Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis

详细信息    查看全文

• 作者：Michelle J. Ormseth ; Patricia G. Yancey ; Joseph F. Solus ; S. Louis Bridges Jr. ; Jeffrey R. Curtis ; MacRae F. Linton ; Sergio Fazio ; Sean S. Davies ; L. Jackson Roberts II ; Kasey C. Vickers ; Valentina Kon ; C. Michael Stein and the TETRAD Investigators
• 刊名：Arthritis & Rheumatism
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：68
• 期：9
• 页码：2099-2105
• 全文大小：123K
• ISSN：1529-0131

文摘

Patients with rheumatoid arthritis (RA) have an increased risk of coronary heart disease (CHD). Some RA therapies may modify this risk, but the underlying mechanisms are unclear. The cholesterol efflux capacity of high-density lipoprotein (HDL) is associated with a reduced CHD risk in non-RA populations; however, inflammation may impair the function of HDL. The aim of this study was to evaluate whether reduced inflammation resulting from treatment with methotrexate (MTX), adalimumab (ADA), or tocilizumab (TCZ) would increase the net cholesterol efflux capacity of HDL in patients with RA.